Open an account

Tempus AI

TEM · NASDAQ

$66.75+$2.41 (+3.75%)TodayMarket closed ·
Prev close $64.34

About TEM

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. The company is headquartered in Chicago, Illinois and currently employs 3,800 full-time employees. The company went IPO on 2025-05-30. The company offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. The company provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.

Employees
3,800
Headquarters
Chicago, Illinois
Listed
May 30, 2025
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
investors.tempus.com

TEM key statistics

Market cap
12.04B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
6.91M
Volume
4.99M
Open price
$64.00
High today
$69.07
Low today
$63.20
52 Week high
$96.29
52 Week low
$40.77

Tempus AI (TEM) at a glance

As of Oct 20, 2026, Tempus AI (TEM) shares are priced at $66.75, giving the company a market cap of 12.04B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $63.20 and $69.07. The current price is 5.6% above the day's low and 3.4% below its high.

Volume so far is 4.99M shares, below the average of 6.91M shares a day.

Over the past year Tempus AI has ranged from $40.77 to $96.29, and now sits 47% of the way up that range.

Tempus AI met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported -$0.04 per share against an estimate of -$0.1411.

The average analyst price target is $71.92, 7.7% above the current price, from 18 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

61%of 18 analyst ratings say Buy
  • Buy61.1%
  • Hold33.3%
  • Sell5.6%
Price target · 22 analystsAvg $71.92
Low
$35.35
Now
$66.75
High
$105.00

TEM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 25.4% on average.

  1. Q3 FY24: reported -$0.25 per share against an estimate of -$0.3131
  2. Q4 FY24: reported -$0.18 per share against an estimate of -$0.2033
  3. Q1 FY25: reported -$0.24 per share against an estimate of -$0.2891
  4. Q2 FY25: reported -$0.22 per share against an estimate of -$0.2449
  5. Q3 FY25: reported -$0.11 per share against an estimate of -$0.1695
  6. Q4 FY25: reported -$0.04 per share against an estimate of -$0.0422
  7. Q1 FY26: reported -$0.13 per share against an estimate of -$0.1935
  8. Q2 FY26: reported -$0.04 per share against an estimate of -$0.1411

TEM news

  • Press releaseBusiness Wire

    Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

  • Press releaseBusiness Wire

    Tempus to Report Third Quarter 2026 Financial Results on November 2

  • Press releaseGlobe Newswire

    The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking Shape

  • Press releaseBusiness Wire

    Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases

  • Namrata Sen

    Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’

  • Vandana Singh

    Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure

  • Press releaseBusiness Wire

    Tempus Announces Multi-Year Collaboration with Moderna and Merck

  • Rishabh Mishra

    Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an ‘Incorrect Comparison’

Similar companies

Companies in the same industry as Tempus AI

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.